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Abstract
Since 1990 certain health claims in the labelling and marketing of food products have been allowed in Sweden
within the food sector’s Code of Practice. The rules were developed in close dialogue with the authorities. The
legal basis was a decision by the authorities not to apply the medicinal products’ legislation to ‘‘foods
normally found on the dinner table’’ provided the rules defined in the Code were followed. The Code of
Practice lists nine well-established diethealth relationships eligible for generic disease risk reduction claims in
two steps and general rules regarding nutrient function claims. Since 2001, there has also been the possibility
for using ‘‘product-specific physiological claims (PFP)’’, subject to premarketing evaluation of the scientific
dossier supporting the claim. The scientific documentation has been approved for 10 products with PFP, and
another 15 products have been found to fulfil the Code’s criteria for ‘‘low glycaemic index’’. In the third
edition of the Code, active since 2004, conditions in terms of nutritional composition were set, i.e. ‘‘nutrient
profiles’’, with a general reference to the Swedish National Food Administration’s regulation on the use of a
particular symbol, i.e. the keyhole symbol. Applying the Swedish Code of practice has provided experience
useful in the implementation of the European Regulation on nutrition and health claims made on foods,
effective from 2007.
Keywords: disease risk reduction; functional foods; nutrient functions; nutrients; other substances; scientiﬁc
substantiation
Introduction and background
T
he first edition of the Swedish Food Sector’s
Code of Practice on health claims in the
labelling and marketing of food products
(hereafter referred to as ‘‘the Code’’) was published
and implemented in August 1990. The background
was the increasing scientific documentation of diet
health relationships as a basis for national and
international nutrition recommendations and diet-
ary guidelines based on this science. The food
industry showed an increasing interest in providing
products with nutritionally adapted composition
and wanted to claim health benefits in their market-
ing of such products.
In Sweden, there was an increasingly intense
debate as to whether it was reasonable to have on
the one hand official dietary recommendations
aiming at preventing diet-related diseases, and on
the other hand a complete prohibition of any health
claims with reference to the medicinal products
legislation, even regarding well-established and gen-
erally recognized diethealth relationships (1). In
1988, a large producer of margarines made far-
reaching advertisements for a product high in
polyunsaturated fat, which was said to be good for
people with high cholesterol values. The medical
products division of the National Board of Health
and Welfare (now the Swedish Medical Products
Agency) argued that this was illegal sale of drugs.
The marketing was withdrawn. As a result of this
case and the above-mentioned discussions, a
working group representing the authorities decided,
in 1989, that ‘‘medicinal products legislation should
no longer apply to foods normally found on the
dinner table’’ (2). One condition for this was that no
dosage instructions or other information used only
for medicinal products be used in the marketing. The
exception did not include preparations sold in
pharmaceutical-like forms, such as tablets or cap-
sules, even if these were made from food raw
materials.
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increasing focus on the primary responsibility of
companies to prevent and solve consumer and
marketing problems. For these reasons voluntary
measures in the form of self-regulating programmes
appeared. Accordingly, the authorities encouraged
the food sector to establish such a self-regulating
programme regarding the use of health claims in the
labelling and marketing of food products (2).
Development of the first edition of the Code
The first edition of the Code, from 1990 (2), was
developed in consultation with the competent
authorities and their expert group on diet, health
and physical activity, and closely related to the
official nutrition recommendations. The principals
of the Code were the main organizations of food
manufacturers and retailers, at present the Swedish
Food Federation (Li) and the Swedish Food Re-
tailers Federation, respectively. The SNF Swedish
Nutrition Foundation had an advisory and co-
ordinating role. A health claim was defined as a
statement on a health-related advantage of a food
product, e.g. in relation to description of the
composition of the food. The Code focused
around generally accepted diethealth relationships
(Table 1).
As important general rules, it was stated that
marketing and information using health claims
should contribute to consumers’ insight into the
diethealth relationship, and that claims should be
concordant with general nutrition recommenda-
tions and have generally recognized scientific sup-
port. Health claims should be made in relation to a
balanced diet and used only for products that with
normal use have an impact on the total dietary
composition.
In the first edition (2) there was a specific
comment about general, vague claims such as
‘‘good for the skeleton, the heart, the stomach’’
and ‘‘normalizes the intestinal flora’’. Such claims
should be used sparingly and only in combination
with an explanatory text, and must be established
and documented.
Regarding product-specific claims implying that a
certain product has an effect on, for instance, blood
cholesterol or blood pressure, it was stated that such
claims require well-documented and published stu-
dies of the product or an identical product. Since
delimitation towards medicinal products was re-
garded as difficult in such cases, premarketing
consultation with the Medical Products Agency
was recommended.
Claims about blood glucose reducing effects were
not allowed in the first edition, with reference to the
fact that foods for people with diabetes were not
approved as foodstuffs for particular nutritional
uses in Sweden. Further, no claims were allowed
regarding any dietcancer relationships, which was
in any case not explicitly wished for by the industry.
An internal evaluation in 1993 (4) concluded that
health claims had been made mainly for spreads,
edible oils and fermented milk products, and also
for cereals, mineral salts and mineral water, and that
at least 30 new products with health claims had been
launched. Regarding product-specific claims, the
experience, particularly from marketing of probiotic
products, indicated the need for premarket evalua-
tion of the scientific documentation.
Second edition, effective from 1997
A revision of the Code was made in 199496 and the
second edition of the Code was applicable from
1997 (3). At that time, the Swedish food legislation
had been harmonized with that of the European
Union (EU) (from 1994 within the European
Economic Agreement; Sweden became an EU
member from 1995). The most important points in
the revision were that:
. A health claim, defined as an assessment of the
positive health effects of a foodstuff, must consist
of two steps: information on the diethealth
relationship, followed by information on the
composition of the product. Only this type of
Table 1. Diethealth relationships approved for generic health claims according to
the Swedish Code of Practice: wording according to the two-step principle was
required from the second edition (3)
1. Obesity: reduced energy content
2. Cholesterol level in the blood: reduction of saturated fat intake, and
certain types of soluble, gel-forming types of dietary fibre
3. Blood pressure: reduction of salt (sodium chloride)
4. Atherosclerosis: reduction of the diet-related risk factors blood pressure
and cholesterol level, and omega-3 fatty acids from fish (added in 1997)
5. Constipation: dietary fibre
6. Osteoporosis: calcium intake
7. Caries: absence of sugars and other easily fermented carbohydrates
8. Iron deficiency: iron content in foods
9. A healthy lifestyle and well-balanced diet high in wholegrain products (a)
reduces the risk of coronary heart disease, and (b) reduces the risk of
heart disease. Product XXXX has a high wholegrain content (Y%
wholegrain) (exact wording required) (added in 2003)
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revised Code, and examples of approved and
non-approved claims were given in an appendix.
. More clear distinctions were made between
health claims, nutrition claims and nutrient
function claims.
. A claim regarding naturally occurring omega-3
fatty acids in fish/fish products and risk of
atherosclerosis and associated cardiovascular
diseases was introduced.
. A special comment was made that claims regard-
ing the effect of a foodstuff on the blood sugar
level after a meal may fall within the framework
of nutrient function claims, provided that the
claims are not related to disease or the risk of
disease. An example of a claim regarding a
generally accepted property of this kind was
given: ‘‘The carbohydrates in pasta lead to a
low, slow increase in blood sugar level’’ (the
glycaemic index was more specifically addressed
in the 2004 edition of the Code; see below).
. The previous possibilities for product-specific
claims within the Code were removed.
In spite of increasing evidence of associations
between intake of fruit and vegetables and lower
risk of several cancers, claims regarding diet and
cancer were excluded also from the revised pro-
gramme, which was explicitly required by the
competent authorities. One reason was difficulties
in applying the two-step principle, since possible
protective effects could not be connected with
specific food components.
With these revisions, the competent authorities
continued to support the Code, and a reference to it
was kept as ‘‘general advice’’ in the Ordinance on
Labelling and Presentation of Foodstuffs (5).
Towards product-specific physiological claims
The increasing interest in developing foods with
health benefits above ‘‘normal nutrition’’ warranted
a special comment in the revised Code (3): ‘‘It is the
intention of the food industry to take up the matter
of ‘functional foods’ in a supplement to this
programme.’’ One main reason for this was the
great interest in Sweden in developing microorgan-
isms with specific health-promoting effects and
market probiotic products containing such micro-
organisms with health claims. Numerous and often
far-reaching health claims appeared on the market.
The authorities made interventions prohibiting
certain claims, but there were problems in classify-
ing these products. Some were temporarily regis-
tered as ‘‘natural remedies’’. Claims regarding
effects of oligosaccharides on the intestinal flora
(bifidogenic effects) also started to appear on the
market. In 1996, the National Food Administration
(NFA) listed a number of prohibited claims for
probiotics (6), some of which, however, have
continued to be used in the marketing of such
products.
A working group was set up within the SNF and,
in 1998, formulated a proposal for an extension of
the Code to cover also ‘‘Product-specific physiolo-
gical claims’’, abbreviated to PFP in Swedish (79).
At that time the Functional Foods Science in
Europe project, FUFOSE, was about to be com-
pleted (10). In this project, ‘‘enhanced function
claims’’ and ‘‘disease risk reduction claims’’ were
specified, and the distinction was made between
claims about disease risk reduction through a
suitable diet including ‘‘functional foods’’ and
prevention that can be claimed only for medicinal
products. FUFOSE suggested that disease risk
reduction claims should be allowed for food pro-
ducts if an effect on an established marker (risk
factor) had been demonstrated. The development of
the Dutch ‘‘Code of Practice assessing the scientific
evidence for health benefits stated in health claims
on food and drink products’’ (11) provided another
important input in this work.
The PFP corresponded mainly to ‘‘enhanced
function claims’’, and was defined as meaning ‘‘a
claim concerning the health-promoting effect of the
product in itself’’. As for other parts of the Code,
the products should be part of a normal diet and
not dietary supplements or other substances in the
form of capsules, tablets, drage ´es, powders or the
like. Human intervention studies were required,
performed on study groups representative of the
intended consumers, with realistic amounts of the
product related to normal use and long enough to
show a lasting effect. Premarketing evaluation by
internationally well-reputed scientists was required.
Furthermore, a new lawyer-led body for follow-up
was suggested, ‘‘The Assessment Board for Diet
Health Information’’ (abbreviated to BKH in Swed-
ish).
Later in the same year, 1998, the NFA published,
on the request of the Government, its first report
with an analysis of health claims (12, 13). The legal
situation in different countries was described and
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were discussed. The previous standpoint was main-
tained that generic claims in two steps, based on
well-documented diethealth relationships, could be
accepted without considering the product as a
medicine even if a specific disease was mentioned.
The need for additional considerations was ex-
pressed, especially in relation to developments that
had started within the EU, for instance regarding
the possibility of using product-specific claims
without interference with the medicinal products
legislation.
In 1999 there were interpellations and questions
in the Swedish Parliament regarding product-spe-
cific health claims. The Minister of Agriculture
responded and the Department of Agriculture
arranged hearings with stakeholders. The Govern-
ment assigned the NFA to clarify (after consultation
with the Medical Products Agency and the Swedish
Consumer Agency) reasons for enabling product-
specific health claims, and to provide a basis for
further input in the continued work within the EU.
This report was published in April 2000 (14, 15).
The main alternative was regulation of product-
specific health claims, implying application to the
competent authority and approval of both the
product and the health claim. A possibility men-
tioned awaiting EU regulation was to extend the
Code to include product-specific physiological
claims according to the PFP report (7), which was
attached as an appendix to the report. In a third
report in June 2001 (16) the NFA included a further
analysis of ‘‘functional foods’’ and focused on
suggestions on a legal framework that could be
compatible with the forthcoming EU Regulation, as
well as on documentation of effects and safety
aspects.
In response to a further interpellation in Parlia-
ment on 27 March 2001, the Minister of Agriculture
invited the SNF to develop the Code according to
the PFP report (7) in collaboration with the food
sector and the consumer organizations that had
previously expressed their support for an extended
Code (17). This was also regarded as a possible
temporary solution in the analysis by the NFA (16).
The extension of the Code to product-specific
physiological claims was launched from September
2001 (18).
The extension of the Code included a specific
body for follow-up: the Assessment Board for Diet
Health Information (BKH). The task of this new,
lawyer-led body, as regulated in its statutes (19),
includes issuing statements, either on its own
initiative or on request from a private person,
manufacturer, a coalition of manufacturers, consu-
mers or employees concerning whether a particular
marketing action or other action relating to the
labelling or marketing of foods complies with good
business practice according to the Code (19, 20).
The 2004 edition of the Code
The second revision of the Code was carried out in
20032004 and a third edition (20) became effective
in September 2004. As in the previous editions,
general reference was made to labelling regulations,
directives and practices requiring that marketing
information be reliable, objective and not mislead-
ing. The following main new items and completions
were made:
. It was specifically stated that health claims dealt
with in the Code included ‘‘all claims related to
health, performance and well-being’’.
. The different types of health claims dealt with in
the Code  two types of generic claims, i.e.
nutrient function claims and generic reduction
of disease risk claims, and product-specific phy-
siological claims  were more clearly defined and
illustrated by examples.
. The additional generic disease risk reduction
claim regarding wholegrain and risk of (coron-
ary) heart disease, No. 9, introduced in 2003, was
included.
. Conditions for use of the various types of claims
in terms of nutritional composition of eligible
products, i.e. nutrient profiles, were introduced.
Appendices 13 of the Code (20) are reproduced
as appendices to this article. Appendix 4 contains
the statutes of BKH (19) and Appendix 5 comments
on nutrition claims with reference to relevant
regulations, nutrition declaration/labelling with list-
ing of vitamins and minerals that may be declared,
the keyhole symbol, recommendations regarding
product groups, and claims regarding blood sugar
and cholesterol.
Table 2 shows the different claims specified in the
Code, compared with health claims according to the
Codex Alimentarius Guidelines (21) and the EC
Regulation effective from 1 July 2007 (22, 23).
Product-specific physiological claims would corre-
spond primarily to other function claims in the
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ably apply to Article 13 in the EC Regulation,
together with the nutrient function claims.
Generic claims
Regarding nutrient function claims, it was stated in
the Code (20) that such claims ‘‘may only be made
for generally accepted nutritional physiological
functions ...’’ and that ‘‘...functions shall also be
relevant for Swedish consumers.’’ It was recom-
mended, but not absolutely required to express
nutrient function claims in two steps, i.e. a nutrition
claim combined with information about a certain
generally accepted physiological role of the nutrient
in question. Some examples of acceptable nutrient
function claims that were considered relevant to
Swedish conditions were given in an appendix, as
well as some examples of scientifically true, but for
Swedish conditions irrelevant claims (Appendix 1).
However, the Code did not provide any positive list
of nutrient function claims, which will be estab-
lished according to Article 13 in the new EC
Regulation (22, 23). Nutrition labelling that in-
cludes the nutrient in question was required ex-
plicitly, which means that the amount of the
nutrient must meet the labelling conditions, e.g.
15% of recommended daily intake (RDI) per 100 g
or 100 ml.
The generic reduction of disease risk claims, listed
in Table 1 and Appendix 2, with examples of
wordings, are closely related to the official Swedish
Nutrition Recommendations (1996 or later updates,
now based on 24), and thus relate to generally
recognized and scientifically well-documented con-
nections between diet and a reduced risk of diet-
related diseases.
Regarding wording, as in the previous edition, the
requirement is stated that ‘‘Generic reduction of
disease risk claims must be given in two separate
parts, that is, information on the product’s compo-
sition and the generally accepted connection be-
tween diet and a reduced risk of disease.’’
The requirement to put the claim into a dietary
context was worded as follows: ‘‘A claim must
provide enough information to enable the consumer
him-/herself to evaluate the claim and must give a
balanced overall picture of the cause and effects
described in the marketing. The wording of generic
reduction of disease risk claims must therefore take
into account the requirements for the composition
of a balanced diet that provides all of the different
nutrients.’’ This is in agreement with Article 3d in
the EC Regulation (22).
Nutrient profiles
Nutrient profiles were specified in the third edition
of the Code, as given in Appendix 2. In previous
editions general conditions regarding the nutri-
tional composition of products with health claims
had been expressed, e.g. to ‘‘promote a generally
nutritious diet’’ or ‘‘not clash with dietary guide-
lines’’. For disease risk reduction claims the key-
hole criteria were generally required when
applicable. Since the keyhole criteria were under
revision at that time, complementary conditions for
sugars and fat, for example, were specified by the
Code. However, when the revision of the keyhole
rules was completed on 1 June 2005, the new
conditions, including maximum levels for the con-
tent of fat, sugars and salt and minimum levels of
dietary fibre, were adopted (25). The keyhole
criteria are category based, and vary for the 26
different food groups included. However, the Code
allows claims for a few product categories not
covered by the keyhole rules, e.g. vegetable oils, and
additional conditions for these products were
therefore
established.
Product-specific claims
Regarding product-specific physiological claims, a
premarketing evaluation procedure for the scientific
substantiation of claims had been organized by
SNF, and the requirements were defined as follows:
Table 2. Claims speciﬁed in the Swedish Code, compared with Codex Alimentarius guidelines (21) and EC Regulation (22)
Swedish Code 2004 Codex Alimentarius guidelines 2004 EC Regulation 2007
Nutrient function claims (generic);
product-specific physiological claims
Nutrient function claims;
other function claims
Article 13. Health claims other than those referring to the
reduction of disease risk and to children’s development and health
Reduction of disease risk claims (generic) Disease risk reduction claims Article 14. Reduction of disease risk claims and claims referring to
children’s development and health
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viated PFP in Swedish) must be substantiated
by studies that demonstrate the claimed effect
using scientifically sound methods. The com-
pany marketing the product must be able to
provide documentation of these studies. The
studies must be conducted on humans and
the trial group used should be representative
of the product’s target group. The studies must
represent intake levels that correspond to nor-
mal use of the food for the trial period, and be
of sufficient duration to demonstrate the in-
tended effect.
The handling process for documentation submitted
to SNF for scientific evaluation is described in
Appendix 3. SNF’s research committee had the task
of selecting appropriate experts to carry out the
evaluation on a case-by-case basis (18).
It was further stated:
The food product must provide a specific,
documented physiological effect and be in-
tended for consumption as a part of a nutri-
tionally balanced diet. Characteristically, the
product is marketed with claims related to this
effect. The product must have a declaration of
nutritional value according to group 2 ...and
must state the amount to be consumed to
achieve the claimed physiological effect.
Ingredients of the foods evaluated for PFP
claims must be classified as food raw materials
or approved additives, and where applicable
must have undergone safety testing in accor-
dance with the EC Regulation on novel foods.
SNF makes sure that this is the case before
beginning an evaluation. The Research Com-
mittee or experts retained by the committee do
not, as a rule, make decisions concerning safety
issues.
Since the introduction of product-specific physio-
logical claims in 2001, 34 applications for evaluation
of scientific dossiers have been handled, together
with 18 applications for evaluation of the ‘‘low
glycaemic index’’ claim according to the simplified
procedure described below (August 2007). The
11 products with approved documentation have
claims related to blood glucose excursions, mild
gastrointestinal complaints and blood cholesterol/
low-density lipoprotein cholesterol levels (Table 3).
In addition, 15 products (including ready-to-eat
meals, breads, mueslis and a snack meal) have
been approved for the use of a ‘‘low glycaemic
index’’ claim (26).
In the Netherlands product-specific claims have
been permitted according to the Dutch ‘‘Code of
Practice assessing the scientific evidence for health
benefits stated in health claims on food and drink
products’’, introduced in 1998 on the initiative of
the Netherlands Nutrition Centre (11). This Code
regards voluntary evaluation of the scientific evi-
dence behind planned product-specific health
claims on foods and drinks. At the time of writing
(September 2007), eight products have passed this
evaluation with a positive result, as listed in Table 4.
Comments on specific issues related to the
Swedish Code
The two scientific expert panels related to the Code
have been the NFA’s expert group on diet and
health, and SNF’s research committee. Some issues
handled by these expert groups at the latest revision
and more recently are commented on below. For the
generic claims, discussions have been closely related
to the official nutrition recommendations, and a
reference to the scientific basis for these has
Table 3. Products with documentation approved for product-speciﬁc physiological claims (September 2007) (26)
Product Manufacturer (year) Description Physiological claim
Primaliv Ska ˚nemejerier, Sweden (2002) Yoghurt and muesli with beta-glucans Blood glucose levels
Becel pro.activ (with plant sterols) Unilever Sverige (2002) Yoghurt drink (shot), milk drink and spread Blood cholesterol level
ProViva (with Lactobacillus plantarum 299v) Ska ˚nemejerier, Sweden (2003) Fruit drink and shot Intestinal gas formation
Julia/Hja ¨rtans Lust Ska ˚nemejerier, Sweden (2004) Margarine cheese based on rapeseed oil Blood cholesterol level
Benecol (with plant sterols) Raisio, Finland (2006) Spread and yoghurt drink Blood cholesterol level
LGG
†
Plus (with L. rhamnosus GG, L. rhamnosus
Lc705, P. freudenreichii ssp. shermanii JS and
B. animalis/lactis)
Valio, Finland (January 2007) Milk drink Bowel comfort
Primaliv muesli Ska ˚nemejerier, Sweden (2006,
posted sept 2007)
Muesli with beta-glucans Blood cholestrol level
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related to generic claims approved in the UK,
according to the Joint Health Claims Initiative
(JHCI), established in 2000 (27) as a joint ven-
ture between consumer organizations, enforce-
ment authorities and industry trade associations.
This Code of Practice defines both generic and
product-specific (innovative) claims. Until closing
down on 31 March 2007, however, only generic
claims (Table 5) had been approved. In addition to
the JHCI claims, claims approved by the US Food
and Drug Administration (FDA) have been con-
sidered.
Certain types of soluble dietary fibre and blood
cholesterol
Regarding claims on the connection between certain
types of soluble fibre and blood cholesterol levels, it
was recommended in the third edition of the Code
(20) that such claims be used primarily for oat fibre
(beta-glucans, Appendix 2, Connection 2b). This
was based on the broad consensus on the choles-
terol-reducing effect of oat beta-glucan, expressed in
the adoption of the corresponding claim by the
FDA in 1997 (28) and later on also by the JHCI
(27). The requirements set by the FDA, that
products eligible for this claim should provide at
least 0.75 g beta-glucan per normal serving or 3 g
beta-glucan per day at a normal amount consumed,
were adopted. The claim was approved for rolled
oats and oat bran, as well as mixtures that contain
these raw materials. Since some food processing can
affect the chemical structure of the beta-glucans and
thereby reduce the cholesterol-lowering property,
substantiation of a retained cholesterol-lowering
effect was required for processed foods.
Recently, SNF’s research committee reviewed the
documentation on cholesterol-lowering effects of
barley beta-glucans (29), and concluded that the
claim could also be used under similar conditions
for barley beta-glucans. Accordingly, the Code also
approved the use of this generic claim for barley
flour and flakes (30).
Soya protein
A claim regarding cholesterol-lowering effect of
soya protein, approved by the FDA and later also
by the JHCI, was considered, but rejected by the
expert group on diet and health as less relevant for
Swedish conditions.
Omega-3 fatty acids
When introduced in the 1997 edition (3), claims on
the reduced risk of cardiovascular disease were
Table 4. Products that have passed the scientiﬁc evaluation within the Dutch Code with a positive result (11)
Product Health claim Year
1. Phytosterol-enriched margarine (Becel pro.activ) LDL-cholesterol lowering 1999
2. Bread with added n-3 LC-PUFAs (O’mega) Lower risk of fatal coronary heart disease 2000
3. Phytostanol ester-enriched margarine and yoghurt (Benecol) LDL-cholesterol lowering 2001
4. Bread with added prebiotic (Vitalbrood, Frutafit inulin) Bowel function 2003
5. Yoghurt with probiotic (Activia, L. bifidus Essensis) Bowel function 2004
6. Bread with added OatWell fibre (Pro ´-FIT) LDL-cholesterol lowering 2005
7. Yoghurt with probiotic (L. GG, Vifit) Intestinal barrier function 2006
8. Fermented milk product (L. casei Shirota, Yakult) (1) Improved bowel habit in subjects who are susceptible
to constipation, and (2) support of a well-balanced microbiota
through an increased number of lactobacilli
2006
LDL: low-density lipoprotein; LC-PUFA: long-chain polyunsaturated fatty acid.
Table 5. Approved generic claims within the UK Joint Health Claims Initiative
(JHCI) (27)
Date Claim
12 October 2001 Generic health claim for reduced saturated fat and blood
cholesterol
04 February 2002 Generic health claim for wholegrain foods and heart
health
27 July 2002 Generic health claim for soya protein and blood
cholesterol
06 May 2004 Generic health claim for oats and blood cholesterol
11 February 2005 Generic health claim for omega-3 PUFAs and heart health
Under consideration but not available for use under current food law
15 February 2002 Generic health claim for fruit and vegetables and stomach
cancer
15 February 2002 Generic health claim for fruit and lung cancer
15 February 2002 Generic health claim for vegetables and bowel cancer
PUFA: polyunsaturated fatty acid.
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omega-3 fatty acids. In the third edition the claim
was extended to be allowed also for other foods with
added fish oil, provided that the content of omega-3
fatty acids in the final product was at least 0.7 g per
100 g, or per serving for products packaged as single
servings (Appendix 2, Connection 4).
When detailed conditions of use were established
in 2004, the general principle applied to disease risk
reduction claims was that foods eligible for a claim
shall be a ‘‘significant source’’ of the nutrient in
question, i.e. contain 30% of the RDI per 100 g, or
per portion for products packaged as single ser-
vings. However, for omega-3 fatty acids ‘‘significant
source’’ was not defined in the Directive on labelling
(31). Therefore, it was decided to base the condition
of use on the nutritional recommendation of a daily
intake of 1E% total omega-3 fatty acids (24).
Calculated on a daily energy intake of 2000 kcal,
30% of RDI is 0.7 g omega-3 fatty acids. The Code
states that foods containing this amount per 100 g
or portion for products packaged as single portions
can use a nutrition claim ‘‘high in omega-3 fatty
acids’’, and if the level is half of this (i.e. 15% of
RDI) a nutrition claim ‘‘contains omega-3 fatty
acids’’ may be used.
Health claims regarding decreased risk of cardi-
ovascular disease were allowed only for foods high
in long-chain omega-3 fatty acids from fish, and not
for those high in omega-3 fatty acids from vegetable
oils (a-linolenic acid). Although the level of omega-
3 fatty acids set as a condition for this claim, 0.7 g
per 100 g, was derived from recommendations of
total omega-3 fatty acids intake, both SNF’s
research committee and NFA’s expert group on
diet and health supported the condition for using
the claim to be 0.7 g omega-3 fatty acids from fish
per 100 g, i.e. long-chain omega-3 fatty acids. The
rationale behind this was that the claim is based on
epidemiological studies showing a connection be-
tween intake of fish and a lower incidence of
cardiovascular disease, as well as intervention
studies using gram doses of long-chain omega-3
fatty acids. For example, one portion of fish
provides 15( 10) g long-chain omega-3 fatty
acids.
The JHCI approved a generic claim on omega-3
fatty acids in 2005 (Table 5). For that claim, 0.2 g
omega-3 fatty acids per serving is required for foods
presented as a standalone serving. However, the
following statement is also required: ‘‘The Govern-
ment advises that at least two servings of fish, one of
which should be oily, containing approximately 3 g
long-chain n-3 polyunsaturated fatty acids, is con-
sumed per week.’’
In the EC Regulation both nutrition claims and
health claims regarding omega-3 fatty acids en-
counter problems since the Annex to the Regulation
does not list any claims corresponding to ‘‘high in
omega-3 fatty acids’’ and the labelling directive (31)
does not define ‘‘source of omega-3 fatty acids’’.
However, in 2005 EFSA suggested the nutrition
claims ‘‘omega-3 fatty acid source’’ and ‘‘high in
omega-3 fatty acids’’ for foods containing 15% and
30% of the recommended nutritional intake (2 g per
day) per 100 g, 100 ml or 100 kcal, respectively (32),
which is slightly lower than the levels used in the
Code. The proposed claims did not distinguish
between short-chain and long-chain omega-3 fatty
acids. However, it would be helpful if conditions for
claims for both of these categories of omega-3 fatty
acids were introduced in the Annex to the EU
Regulation (22).
Dietary fibre
For the fifth claim, on dietary fibre and bowel
regularity/decreased risk of constipation, products
are required to comply with the keyhole criteria
when applicable and to have ‘‘high’’ content of
dietary fibre (Appendix 2, Connection 5). At the
time of the latest revision, ‘‘high fibre’’ was defined
as at least 3.5 g dietary fibre per 1000 kJ. In 2005
this was changed to comply with the new keyhole
criteria, i.e. 4.5 g per 1000 kJ (25). Furthermore,
normal consumption of the product should provide
at least 5 g dietary fibre, which is 20% of the
minimum recommended intake of dietary fibre. If
more than 20% of the fibre was derived from fibre
concentrates or isolates, substantiation of laxative
effects was required.
Wholegrain
In 1999, the FDA allowed use of the following
health claim: ‘‘Diets rich in wholegrain foods and
other plant foods and low in total fat, and saturated
fat, and cholesterol may reduce the risk of heart
disease and some cancers’’. In 2002, the JHCI
published an authoritative endorsement that whole-
grain foods are associated with a healthy heart, and
allowed the following claim: ‘‘People with a healthy
heart tend to eat more wholegrain foods as part of a
healthy lifestyle’’ (27, 33, 34).
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the Code in 2003 as supported by NFA’s expert
group on diet and health and by SNF’s research
committee, which stated:
After having considered the epidemiological
studies and reviews available, the research
committee expressed the following opinion:
There is a consistent epidemiological associa-
tion between consumption of wholegrain cereal
products and lower risk of ischaemic (coronary)
heart disease (IHD). The relationship is seen in
different populations and at different levels of
intake. The relationship is stronger for whole-
grain than for cereal fibre. It is not known
which component(s), or combination of com-
ponents, that convey the protective effect.
Intervention studies are lacking. The surveys
published as review articles, and the recent
evaluation within the UK JHCI can be regarded
as sufficient to support the epidemiological
relationship between consumption of whole-
grain cereal products and a ‘‘healthy heart’’,
i.e. diminished risk of IHD (33).
The reason for requiring an exact wording for this
claim according to one of two alternatives, i.e.
mentioning lifestyle and well-balanced diet, was
the fact that this claim is based mainly on observa-
tional, i.e. epidemiological studies in which the
wholegrain consumption covariates with other po-
sitive lifestyle factors. A similar view is reflected in
the claim as approved by the JHCI (27).
The conditions for the use of the wholegrain
claim according to the Code (Appendix 2) are that
flours, grains and flakes must be 100% wholegrain,
and other products including breakfast cereals and
bread must have at least 50% wholegrain based on
the dry matter. Wholegrain is defined as containing
all components of the grain and limited to wheat,
oats, barley and rye. Furthermore, the dietary fibre
content must be at least 4.5 g per 1000 kJ and
conditions regarding fat, sugar and salt content of
for the keyhole must be fulfilled.
Fruit and/or vegetables
The possibility of introducing a disease risk reduc-
tion claim for fruit and vegetables was further
considered in the 2004 revision, as expressed in a
comment in Appendix 2 (last paragraph). Although
epidemiological studies suggest a connection be-
tween a high intake of fruit and vegetables and
reduced incidence of cardiovascular disease and
certain types of cancer, it was decided not to include
any specific health claims on fruit and/or vegetables.
Instead, reference was made to the possibility of
citing more generally the official recommendation
to eat 0.5 kg fruit and vegetables daily (potatoes not
included).
Although it is still not known which nutrients or
other substances are the most important factors
behind these associations, specific health claims for
fruit and vegetables should be considered further in
analogy with the wholegrain/reduced risk of heart
disease claim.
The JHCI approved claims for fruit and vegeta-
bles and stomach cancer, fruit and lung cancer, and
vegetables and bowel cancer (Table 5). However,
since food law was interpreted as prohibiting
mentioning any disease, these claims were consid-
ered as not available for use.
Glycaemic index
The glycaemic index (GI; incremental area under
the blood glucose elevation after standardized
ingestion of the food product as a percentage of
the corresponding area after glucose) has been the
subject of considerable research recently, and also
controversy regarding its applicability and impor-
tance. It is also used, and misused, extensively in the
public debate, as well as in marketing. GI is
frequently mixed up with glycaemic load (GL,
defined as GIamount of carbohydrate in a
serving, meal or diet).
The handling of GI in the Code was based on
discussions with Scandinavian scientists in the area,
which resulted in a state-of-the-art article (35).
Claims regarding effects on the postprandial blood
glucose level, including claims on low GI, are
considered as product-specific physiological claims
(PFP), with the exception of pasta products, for
which a nutrient function claim is allowed, e.g. ‘‘The
carbohydrates in pasta provide a low and gradual
increase in blood sugar (or have a low GI)’’ (3, 20).
Being a kind of quality measure for carbohy-
drates, related to their rate of digestion and
absorption, specific GI labelling has been regarded
as relevant only for foods providing significant
amounts of digestible carbohydrates, i.e. 15 g or
preferably 20 g per normal serving, and only if there
is a significant variation between different products
within the actual food category. Examples of
products for which GI labelling has not been
considered as relevant so far are cow’s milk
products, since these induce a high insulin response.
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diet, e.g. biscuits high in fat or sugars, have also
been considered as ineligible for GI labelling.
Furthermore, GI labelling has not been approved
for foods where the carbohydrates are mainly added
fructose.
Provided that the criteria specified in Box 1 are
fulfilled, evaluation of the documentation of ‘‘low
GI’’ has been handled by a simplified procedure
(one external expert), compared to other PFP
applications (Appendix 3). Awaiting the implemen-
tation of the EU Regulation, the Code will continue
to provide, through SNF, the opportunity to have a
product evaluated regarding its suitability for label-
ling with low GI, including an evaluation of the GI
determinations used to support the application.
Evaluated products will continue to be listed on
the website of the Code (26).
The Assessment Board for DietHealth
Information
In connection with the extension of the Code in
2001, a new lawyer-led body was set up, the
Assessment Board for DietHealth Information
(BKH), with the following main tasks expressed in
the charter (19, 20):
§2 The assignment of the Board (BKH) is to
make independent statements, on receipt of
queries, as to whether a particular marketing
action or other action in connection with the
labelling and marketing of food products com-
plies with good marketing practice according to
‘‘Health Claims in the Labelling and Marketing
of Food Products. The Food Sector’s Code of
Practice’’, accepted by the responsible organiza-
tions, henceforth called ‘‘the Code’’. A state-
ment by the Board (BKH) is not a substitute for
actions by the authorities concerned.
§3 Appeals may be referred to the Board
(BKH) against decisions by the Research Com-
mittee of SNF Swedish Nutrition Foundation
concerning the evaluation of scientific docu-
mentation according to the Code.
BKH has published 12 statements, one general
guideline type of statement regarding the Code’s
requirement of premarket evaluation of the scien-
tific evidence behind product-specific health claims,
and the other 11 about advertisements and/or panel
texts with health claims. Nine of these statements
concluded that the marketing measure in question
was not in agreement with what can be regarded as
‘‘good marketing practice’’. The statements are
made public and available on the website of the
Code (26).
BKH has not handled any appeals against the
Research Committee’s decisions.
Evaluations of the Swedish Code
An inventory in ordinary shops in March 2000 by
Laser Reuterswa ¨rd (37) indicated that the most
common health claims regarded cholesterol level in
the blood (spreads and products with oats/oat fibre)
and bowel function/regularity. There was also a
Box 1. Criteria for glycaemic index.(GI) labelling according to the Swedish Code (36)
  The GI value of a specific food product must be determined by studies in humans, using the actual food product. Optimal studies are made with
at least 10 healthy subjects, not using drugs that may influence the results. GI determinations should be made in the morning in fasting subjects.
  GI determinations should be made according to the methodology described in the FAO/WHO report ‘‘Carbohydrates in human nutrition’’ (1998).
The GI value must be based on the product’s content of digestible carbohydrates (glycaemic or available carbohydrates), and not on the total
carbohydrate content. Negative areas (i.e. areas obtained when the blood glucose level is lower than the fasting level) should not be included
when calculating the incremental area under the curve (IAUC). The blood glucose level should be determined on capillary blood samples and the
reference (glucose or white bread) should be given to each volunteer at three different occasions.
  Awaiting further standardization of the methodology, GI determinations from at least two independent laboratories are required.
  The product’s GI value should be given in relation to a glucose reference. If the determination is made with white bread as reference, this reference
has to be calibrated against glucose.
  A product is considered to have a low GI if its GI value is lower than 55 (glucose  100) and significantly different from the control in both
determinations.
  The product must contain at least 15 g (preferably 20 g) digestible carbohydrates per normal amount consumed at one eating occasion. For
most products the content of available carbohydrate can be determined ‘‘by difference’’, i.e. the amount of dietary fibre (determined according
to AOAC) is deducted from the total carbohydrate content. However, a specific analysis of the digestible carbohydrates should be made if more
than 5% of the total carbohydrate content may be assumed to consist of non-digestible carbohydrates, that are not determined in the routine dietary
fibre analysis. This is the case mainly for food products with added resistant starch, inulin, oligofructose and other non-digestible oligosaccharides.
  Normally, GI determinations are made on subjects eating an amount of the test product that corresponds to 50 g available carbohydrates. If this results
in an unrealistically large portion of the actual food product, determination may be made with 25 g available carbohydrates from the test product and
reference, respectively.
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function claims, especially for ‘‘PLUS-products’’,
i.e. products enriched with omega-3 fatty acids or
vitamins, for example. About 25 probiotic products
were on the market with more or less strong
product-specific health claims, although such claims
were not allowed at that time, either within the
legislation or within the Code.
A more extensive analysis of wordings and con-
cepts used in health claims was reported in 2001 by
Laser Reuterswa ¨rd and Ungerth (38). Many word-
ings and soft concepts such as ‘‘energy’’ and
‘‘balance’’, not regulated in the Code or elsewhere,
were identified. Messages about probiotic effects,
blood glucose effects, e.g. on satiety, fibre and
satiety, and functional claims for PLUS-products
regarding, for instance, oligosaccharides, omega-3
fatty acids and calcium, were the most common
types of claim.
External evaluation
In 2005 an external evaluation of the Code was
carried out with a focus on the handling of product-
specific physiological claims (39). One reason for
the evaluation was the fact that few products had
passed the scientific evaluation with a positive
statement at that time. The following main conclu-
sions were drawn: (i) the requirements for scientific
documentation of product-specific claims had been
reasonable; (ii) the Assessment Board (BKH) had
been useful but should be completed with a more
active follow-up of health claims used on the
market, and more rapid decisions and actions
against misuses in relation to the Code, than had
been possible by BKH; and (iii) the Code was in line
with the forthcoming EC Regulation, the first draft
having been available since 2003.
Master’s theses
Two master’s (MSc) theses have been written
around the Code. One of them (40) reported that
100 health claims were found on 80 products at an
inventory in 2004 of three supermarkets belonging
to the main retail chains. Of these, 40 were classified
as reduction of disease risk claims, 34 as nutrient
function claims and 26 as product-specific physio-
logical claims (PFP). The product group with most
claims (31 claims) was breakfast cereals and grains;
17 nutrient function claims were found for dietary
fibre and bowel function and nine regarded the
connection between wholegrains and risk of heart
disease. Ten claims were identified that used word-
ing such as ‘‘prevent’’, ‘‘avoid’’ or ‘‘counteract’’,
instead of diminished risk for disease. An overall
conclusion was that the possibility of using generic
claims according to the Code was clearly under-
utilized.
Another MSc thesis had the title ‘‘Wholegrain
and health claims  the industry’s, consumers’ and
scientists’ opinion’’ (41). Data on producers’ and
consumers’ opinions on wholegrain were collected
through qualitative interviews. This survey was
performed in 2005. For surprisingly few consumers
wholegrain was a major reason for choosing a
certain bread, and there was a clear lack of knowl-
edge of and confidence in health claims. Sugar, fat
and fibre content were more commonly considered,
as well as colour and ‘‘coarseness’’. Producers
regarded consumer education a key issue for
increased wholegrain consumption, and expressed
reluctance to mentioning disease risk in their
marketing.
Concluding remarks
The Swedish Code of Practice on health claims, in
action since 1990, has provided experience useful
in the implementation of the EC Regulation on
nutrition and health claims on foods. Based on
these experiences, priorities that may be useful when
establishing positive lists of generic health claims, or
for the responsible use of such claims, are suggested
in an adjacent paper (42). Generic claims, including
disease risk reduction claims in two steps, closely
related to the official nutrition recommendations,
can be used on a range of food products and
thereby help in consumer education and promotion
of healthy diets. Product-specific claims based on
human studies with the food product in question are
few so far, owing to the scientific demands and costs
of such studies. The harmonization within the EC
obtained through the new Regulation can be
expected to provide increased incentives for devel-
oping food products eligible for various types of
health claim.
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Appendix 1: Nutrient function claims:
criteria and examples
Requirements for products making nutrient function
claims
For nutrient function claims regarding vitamins and
minerals, the general requirement is that the product
must contain a ‘‘significant amount’’ (i.e. a minimum of
15% RDI per 100 g or serving
1, Appendix 5) of the actual
nutrient. In addition, normal daily consumption of the
actual product must provide at least 15% RDI of the
nutrient in question. Where applicable, products making
nutrient function claims must meet the criteria for using
the keyhole symbol (Appendix 5), and otherwise con-
tribute to a balanced nutritional diet consistent with
official nutrition recommendations. Nutrient function
claims can with advantage be made in two steps,
according to the examples given below.
Meat, fish, shellfish and poultry products contain
haem-iron with high bioavailability. Nutrient function
claims regarding iron may be made for these products if
the iron content is at least 10% RDI per 100 g or serving,
despite 15% RDI being needed for nutrient declaration.
Normal daily consumption of the actual product must
provide at least 10% RDI of iron.
For products making nutrient function claims regarding
dietary fibre, the product must meet the labelling require-
ments for ‘‘contains dietary fibre’’ (i.e. have a dietary
fibre content of at least 2.5 g per 1000 kJ, Appendix 5). In
addition, normal daily consumption of the actual pro-
duct must provide a minimum of 3.75 g dietary fibre.
2
Examples of approved nutrient function claims relevant
to Swedish conditions
Vitamin C/vitamin E/beta-carotene
3 is an antioxidant
that protects the body’s cells. Product X contains vitamin
C/vitamin E/beta-carotene.
Vitamin C enhances iron absorption. Product Y contains
vitamin C.
Vitamin D helps build bones. Product Z contains vita-
min D.
Calcium helps build bones. Product XX contains cal-
cium.
Zinc is needed for many of the body’s enzyme systems.
Product YY contains zinc.
Iron is essential for (a) making blood cells, (b) production
of haemoglobin. Product ZZ contains iron.
Dietary fibre helps to maintain normal bowel function.
Product XXX contains dietary fibre.
The carbohydrates in pasta provide a low and gradual
increase in blood sugar.
Example of claims that are true, but irrelevant for
Swedish conditions
Vitamin A is found in visual pigments and is important
for night vision. Product X contains vitamin A.
Appendix 2: Generic reduction of disease risk
claims: background, criteria and examples
The following connections between diseases, and their
risk factors, and diet are considered well established
today and can therefore constitute the basis for generic
claims regarding reduction of disease risk in the market-
ing of foods. Every connection is followed here by a short
explanation/background as well as specific criteria. The
basic requirement is that a health claim only be used in
the labelling and marketing of a product that, under
normal use, contributes to a nutritionally balanced diet.
The nutritional composition of a product must be such
that it does not clash with official dietary recommenda-
tions. The nutritional composition and normal amount of
the product consumed must be significant for the
composition of the diet as a whole.
Generic reduction of disease risk claims must be made
in two steps. Table 2 gives examples of how generic claims
about a reduced risk of disease can be worded. With the
exception of Connection 9 (Coronary heart disease 
Wholegrain), however, the exact wording of the claim is
flexible. In the case of Connection 9, only the wording
given in Table 2 may be used. The responsibility for the
appropriateness of the final wording used in labelling and
marketing rests upon the company marketing the pro-
duct. For advice regarding the wording of claims, SNF
Swedish Nutrition Foundation may be contacted.
1. Overweight/obesity  Energy
A high energy intake can lead to overweight/obesity. A
diet with a low or reduced energy content can therefore
reduce the risk for overweight/obesity. Reduced fat
content and increased dietary fibre content lower a
1Only for products packaged in single-serving packages, excluding
milk where a claim may be made also on a larger package, providing
that a normal portion contains at least 15% of RDI.
23.75 g dietary fibre corresponds to 15% of the lowest recommended
daily intake of dietary fibre (25 g).
3According to Nordic Nutrition Recommendations, NNR 2004, 1
retinol equivalent (RE) equals 1 mg retinol (vitamin A) and 12 mg
beta-carotene. RDI for vitamin A is 800 mg (Table 3, Appendix 5),
corresponding to 9600 mg beta-carotene.
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product, reduced sugar content can also contribute to a
lower energy content.
Criteria
Only products with significant relevance to the
total energy intake are appropriate for claims regarding
overweight/obesity. Products carrying this claim must
contain at least 30% less energy per 100 g than a
comparable normal product.
4 For example, the claim
can be made for products in the following product
groups:
dairy products (e.g. yoghurt)
meat products (e.g. sausages)
prepared foods (e.g. complete meals).
Where applicable, the product must also meet
the criteria for using the keyhole symbol (Appendix 5).
For products packaged as single servings, the total energy
content for the serving must be given.
It should be noted that a reduction in sugar content of
solid foods does not normally lead to a lower energy
content. With regard to liquid products, it should be
observed that these may provide less satiety than solid
foods. A considerable amount of energy can therefore
easily be consumed through the intake of certain liquid
products.
2. Cardiovascular disease/atherosclerosis  blood
cholesterol levels
(a) Hard fat
5 (primarily saturated fat)
(b) Certain types of dietary fibre
High cholesterol levels in the blood represent a diet-
related risk factor for atherosclerosis/hardening of the
arteries and are thereby connected with cardiovascular
disease.
Hard fats contribute to elevated blood cholesterol
levels. A nutritionally balanced diet with a low intake
of hard fats can therefore reduce the risk of cardiovas-
cular disease/atherosclerosis. A reduced hard fat content
can be achieved either by a total reduction in fat, or by
substituting hard fats with mono- or polyunsaturated
fats.
Certain types of dietary fibre help to reduce blood
cholesterol levels. A nutritionally balanced diet rich in
these types of fibre can thereby reduce the risk of
cardiovascular disease/atherosclerosis.
Criteria
(2a) Only product groups with significant relevance for
the total fat content of the diet are appropriate for claims
regarding the connection between saturated fat and blood
cholesterol levels (Connection 2a). This applies primarily
to the following groups:
Cooking and baking fats (max. 80% fat), oils (100% fat)
intended for cooking, and dressings (max. 30% fat). A
maximum of 10% of the total fat content can be made up
of hard fat. The total fat content and energy content of
these products must be clearly stated.
Margarine spreads, meat and dairy products. These
products must meet the criteria for using the keyhole
symbol (Appendix 5). A maximum of 30% of the total fat
content can be made up of hard fat.
For all product groups, a maximum of 2% of the total fat
content may be made up of trans fatty acids (not
including naturally occurring trans fatty acids from
animal sources).
Example: In a margarine spread with a total fat
content of 30%, the hard fat content may not exceed
9 g per 100 g and the trans fatty acid content may not
exceed 0.6 g per 100 g of the spread.
For many people, a reduction in total fat consumption is
desirable, and the total fat content should therefore be
clearly stated in the labelling of oils and fats making this
claim. Labelling should also state that the product should
be used sparingly and is meant as a substitute for a
corresponding normal product, and should not represent
an additional source of fat.
(2b) The current recommendation is that claims
regarding a connection between particular types of
dietary fibre and blood cholesterol levels (Connection 2b)
be used primarily for oat fibre (beta-glucans). Some food
processing can, however, affect the chemical properties of
beta-glucans (e.g. molecular weight, solubility and visc-
osity) such that the cholesterol-lowering effect is reduced.
This claim may be used for rolled oats and oat bran, as
well as mixtures that contain these raw materials. For
processed foods containing these, or other raw materials
high in beta-glucans, a retained cholesterol-lowering
effect after processing must be substantiated.
A product making a claim regarding the connection
between oat fibre (beta-glucans) and blood cholesterol
levels must contain 0.75 g of beta-glucans per normal
serving, or provide 3 g per day at a normal amount
consumed. The packaging should clearly state how much
oat fibre (beta-glucans) the product contains as well as
the amount of oat fibre (beta-glucans) that should be
eaten to achieve a cholesterol-lowering effect.
Where applicable, the product must meet the criteria
for using the keyhole symbol (Appendix 5). For example,
the total sugar content (mono- and disaccharides) in
4A ‘‘normal product’’ refers here to a comparable (but not energy-
reduced) product from the same product category. For example,
milk, natural yoghurt and cultured milk products with 3% fat are
considered ‘‘normal’’ products.
5The sum of saturated and trans fatty acids.
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121breakfast cereals must be at most 13%. This corresponds
to approx. 10% added sugar in cereals containing only
cereal grains. According to the Code, the criteria for
added sugars must also be met for other dry products.
For (soft) breads, the added sugar content may not
exceed 7%. For breakfast cereals, the fat content must not
exceed 10%.
3. Cardiovascular disease/atherosclerosis  Blood
pressure Salt
High blood pressure is a diet-related risk factor in
atherosclerosis/hardening of the arteries and therefore
connected to cardiovascular disease. Regular salt (sodium
chloride) contributes to an increase in blood pressure. A
nutritionally balanced diet with a low sodium content can
therefore lower the risk of cardiovascular disease/athero-
sclerosis. A low salt content can be achieved either by
reducing the total salt content or by replacing sodium
chloride with a mineral salt substitute containing potas-
sium.
Criteria
Products making claims regarding the connection be-
tween salt and a reduced risk of cardiovascular disease/
high blood pressure must meet keyhole symbol criteria
where applicable (Appendix 5) and have a lower sodium
content than the limits given below, based on the
product’s finished eating weight.
Sodium
Regular
table salt
Meat, sausages and other meat
products
0.5% 1.2%
Fish products 0.4% 1.0%
Cheese 0.3% 0.7%
Bread 0.3% 0.7%
Crisp bread, crackers and rusks 0.5% 1.2%
Breakfast cereals 0.4% 1.0%
Bouillon, soups and sauces 0.2% 0.5%
Prepared foods 0.2% 0.5%
4. Cardiovascular disease/atherosclerosis/hardening
of the arteries  Omega-3 fatty acids
Epidemiological studies haveshown a connection between
a high intake of fatty fish and a lower incidence of
cardiovascular disease. The long omega-3 fatty acids,
eicosapentaenoic acid (C20:5n-3, EPA) and docosahexae-
noic acid (C22:6n-3, DHA), found in fatty fish have also
been shown to have several positive effects on risk factors
for cardiovascular disease. A nutritionally balanced diet
high in omega-3 fatty acids from fish can therefore
contribute to a reduced riskof atherosclerosis and thereby
associated cardiovascular diseases.
The omega-3 fatty acid found in vegetable oils is
primarily the essential, short omega-3 alpha-linolenic
acid (C18:3n-3, ALA). Risk reduction of cardiovascular
disease is less well documented for short omega-3 fatty
acids than for long omega-3 fatty acids. ALA can be
converted to EPA and DHA in the body, but this
conversion is reliant on many factors.
Criteria
The current recommendation is that claims regarding a
connection between omega-3 fatty acids and cardiovascu-
lardiseasebeusedonlyforfattyfish,productsthereof,and
products containing these raw materials. Products making
thisclaimmustcontainaminimumof0.7 g
6omega-3fatty
acid from fish per 100 g or per serving (applies only to
products packaged as single servings). If the product is
processed in a way that can reduce the bioavailability of
added fatty acids, this must be documented.
5. Constipation  Dietary fibre
Dietary fibre speeds the passage of food through the
intestinal tract and a diet high in dietary fibre can thus
lower the risk of constipation.
Criteria
A product making a claim regarding the connection
between dietary fibre and constipation must meet keyhole
symbol criteria where applicable (Appendix 5). In other
cases, the criterion for ‘‘high fibre’’ must be met (3.5 g
dietary fibre per 1000 kJ, see Appendix 5). Normal daily
consumption of the product must provide at least 5 g of
dietary fibre.
7
According to keyhole symbol criteria, the total sugar
content (mono- and disaccharides) in breakfast cereals
must not exceed 13%. This corresponds to approx. 10%
added sugar in cereals containing only cereal grains.
According to the Code, the same criteria for added sugars
must also be met for other dry products. For (soft) breads,
the added sugar content must not exceed 7%. For break-
fast cereals, the fat content must not exceed 10%.
6Recommendation according to NNR 2004: 1 energy% omega-3
fatty acids. At an energy consumption of 2000 kcal, this corresponds
to 2.2 g of omega-3 fatty acids per day. Similarly to the requirement
for ‘‘high in’’ vitamins and minerals, a product making the nutrition
claim of ‘‘high in omega-3 fatty acids’’ must have a total content of
omega-3 fatty acids corresponding to at least 30% of this amount
(i.e. 0.7 g) per 100 g or serving. For the nutrition claim of ‘‘contains
omega-3 fatty acids’’, the requirement is half this amount. For
claims regarding a reduced risk of atherosclerosis, a product must be
‘‘high in’’ omega-3 fatty acids from fish.
75 g dietary fibre corresponds to 20% of the minimum recommended
daily intake of dietary fibre (25 g).
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122If more than 20% of the fibre content is made up of added
fibre concentrates or isolates, documentation on the
laxative effect of these fibres must be provided.
6. Osteoporosis  Calcium and/or vitamin D
Calcium and/or vitamin D are important dietary factors
for building bones. A nutritional diet high in calcium and/
or vitamin D can therefore reduce the riskofosteoporosis.
Criteria
A product making a claim regarding the connection
between calcium and osteoporosis must be ‘‘high in’’
calcium and/or vitamin D (i.e. 30% RDI per 100 g or
serving
8) (Table 3, Appendix 5). Where applicable, the
criteria for use of the keyhole symbol must also be met
(Appendix 5).
7. Caries  Sugar/fermentable carbohydrates
Frequent intake of products containing sugar and other
easily fermented carbohydrates contributes to the devel-
opment of caries. Products that do not contain sugar and
other fermentable carbohydrates can therefore reduce the
risk of caries.
Criteria
The connection between caries and fermentable carbohy-
drates is primarily applicable to beverages that are
completely free of fermentable carbohydrates.
8. Iron deficiency  Iron
The intake of iron through diet is important, especially
for people with high iron requirements. A nutritionally
balanced diet high in iron can thereby reduce the risk for
iron deficiency.
Criteria
Meat, fish, shellfish and poultry products contain haem-
iron with high bioavailability. These products are there-
fore considered suitable for claims regarding iron defi-
ciency if the iron content corresponds to a ‘‘significant
amount’’ (i.e. 15% RDI per 100 g or serving,
9 Appen-
dix 5, Table 3). Breads and bread mixes, coarsely ground
flours, cereal flakes, breakfast cereals, fruit, vegetables
and legumes making this claim must be ‘‘high in’’ iron
(i.e. 30% RDI per 100 g or serving
8).
The iron content for all products must be based on the
finished eating weight. For beans, this means it applies to
cooked and not dry beans. For flour (and bread mixes), it
means the breads baked with the flour and not the dry
flour.
The criteria for using the keyhole symbol must be
met where applicable, and the fat content must not exceed
10%.
9. Coronary heart disease  Wholegrain
10
Epidemiological studies have shown a connection be-
tween a high intake of wholegrain cereal products,
healthy lifestyles and a lower incidence of (coronary)
heart disease.
Criteria
A product making a claim regarding a connection
between wholegrains and (coronary) heart disease must
have a wholegrain content of at least 50% calculated on
the product’s dry weight. The criteria for use of the
keyhole symbol must also be met where applicable
(Appendix 5). This means a wholegrain content of
100% for flours, flakes and cereal grains, and two-thirds
wholegrain for the flour base of breakfast cereals, a
maximum total sugar content (total mono- and disac-
charides) of 13% for breakfast cereals, gruel and porridge
(not including baby foods) (corresponding to 10% added
sugar for pure grain products), and a maximum of 10%
fat in breads, crackers and rusks, and pasta products.
According to the Code, also breakfast cereals should
contain at most 10% fat. Products such as granola bars,
etc., must meet the same criteria as breakfast cereals.
If a product uses a description such as ‘‘wholegrain
bread’’ or similar, regulations regarding declaration of
ingredients (SLVFS 1993:19) require statement of how
much of the product is wholegrain. A product making a
claim regarding the connection between (coronary) heart
disease and wholegrain must also state the percentage
based on dry weight. Declaration of a product’s ingre-
dients can be formulated as follows: ‘‘Water, wheat flour,
wholegrain rye flour (X%, equivalent to Y% based on dry
weight), sugar, salt.’’
It is desirable that expressions like ‘‘wholegrain
bread’’, ‘‘wholegrain pasta’’, ‘‘ wholegrain flakes’’, etc.,
be used only for products that meet the above criteria.
For products that do not meet the above criteria the
percentage of wholegrain may be stated in a less emphatic
manner, e.g. in the list of ingredients, providing the
wholegrain content constitutes at least 25% of the
product’s dry weight.
Wholegrain refers here to intact or ground whole seed
kernels (i.e. cereal grains where all components contained
in the grain seed, along with the seed shell, are included)
of wheat, oats, barley and rye. 8Applies only to products packaged as single servings. Exceptions to
this are milk and yoghurt, where claims may also be made on larger
packages of the product providing that one normal serving contains
at least 30% RDI.
9Applies only to products packaged as single servings.
10New connection introduced in this version of the Code.
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123Fruit and/or vegetables
Epidemiological studies suggest a connection between a
high intake of fruit and vegetables and reduced incidence
of cardiovascular disease and certain types of cancer. The
picture is complicated, however, when it comes to cancer.
A possible health claim regarding a reduced risk of
disease is under discussion. Until further notice, produ-
cers and marketers are referred to the National Food
Administration recommendation regarding the intake of
0.5 kg of fruit and vegetables
11 daily, which can be used in
the marketing and labelling of foods.
Appendix 3. Product-specific physiological claims:
evaluation of the scientific documentation
For the documentation substantiating a product-specific
physiological claim (PFP), the scientific quality must be
documented by a statement from an independent panel of
experts appointed by the SNF Research Committee. The
task of the Research Committee is to ensure that review
of the documentation’s scientific quality and relevance in
relation to the health benefits the marketing wishes to
present is carried out when an application for evaluation
is made and documentation provided. A panel of experts
comprising at least three internationally well-reputed
researchers in the field is appointed by the Research
Committee. The panel’s task is to issue a written
statement regarding the scientific quality of the docu-
mentation in relation to the desired type of claim. The
evaluation shall, however, not dictate the exact wording
of a claim. This is the responsibility of the company,
preferably after consultation, e.g. with SNF. The process
for evaluation of scientific documentation by SNF
12 is
illustrated in Fig. 1 and is described in more detail below.
For applications for PFP claims regarding a product’s
physiological effect on blood sugar level, a simplified
procedure is used. For more information, please contact
SNF (info@snf.ideon.se, tel 46 (0)46-286-2284).
Review procedure
The evaluation will be carried out as follows:
1) The scientific information on which a product-
specific physiological claim for a food is based is
evaluated on receipt of an application from the
company intending to make such a claim in the
marketing.
Table 2. Examples of appropriate wording for generic reduction of disease risk claims
1 A nutritionally balanced diet with a well-adapted energy content is a key factor in maintaining one’s weight. Product X has a lower energy content than corresponding
normal products.
2
a (a) A nutritionally balanced diet with a low saturated fat content contributes to lower cholesterol levels in the blood and can thereby reduce the risk of cardiovascular
disease/atherosclerosis. Product Y has a low saturated fat content. (b) A nutritionally balanced diet high in soluble fibres from oats (beta-glucans) can contribute to lower
cholesterol levels in the blood and thereby to a reduced risk of cardiovascular disease/atherosclerosis/hardening of the arteries. Product Z is high in soluble oat fibres
(beta-glucans).
3
b A nutritionally balanced diet with a low sodium/salt content can contribute to lower blood pressure and thereby to a reduced risk of cardiovascular disease/
atherosclerosis. Product XX has a lower sodium/salt content than corresponding normal products.
4 A nutritionally balanced diet high in long omega-3 fatty acids from fish and fish products reduces the risk of cardiovascular disease/atherosclerosis. Product YY is high in
long omega-3 fatty acids.
5 A nutritionally balanced diet high in dietary fibre is important for maintaining bowel regularity and reduces the risk of constipation. Product ZZ is high in dietary fibre.
6 A nutritionally balanced diet high in (a) calcium, (b) vitamin D, (c) calcium and vitamin D reduces the risk of osteoporosis. Product XXX is high in (a) calcium, (b) vitamin
D, (c) calcium and vitamin D.
7 Frequent consumption of products containing regular sugar (or other carbohydrates that are easily broken down by bacteria in the mouth) increases the risk for caries.
Product YYY contains no sugar.
8 A nutritionally balanced diet high in iron reduces the risk for iron deficiency. Product ZZZ is high in iron.
9
c A healthy lifestyle and well-balanced diet high in wholegrain products (a) reduces the risk of coronary heart disease, (b) reduces the risk of heart disease. Product XXXX
has a high wholegrain content (Y% wholegrain).
a Claims regarding this connection can be worded to state (1) the connection between hard fats or certain types of dietary fibre and reduction of the risk of cardiovascular
disease/atherosclerosis, or (2) only the connection between hard fats or certain types of dietary fibre and blood cholesterol levels. When using the first alternative, the claim
should clearly state that it is the risk factor ‘‘cholesterol level in the blood’’ that affects the risk of disease.
b A claim must be worded to clearly state that it is the risk factor ‘‘high blood pressure’’ that affects the risk of disease.
c A new claim introduced in this version of the Code. A claim must be formulated according to one of the alternatives given here.
11Does not include potatoes.
12The Assessment Board for Diethealth Information has a
completely different task, namely to assess complaints and
applications regarding marketing actions in relation to the self-
regulating programme. For more information, see Appendix 6.
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1242) SNF is responsible for initiating the evaluation
process as soon as an application is received.
3) From a list of suitable experts, a panel of at least
three experts will be appointed by the SNF Research
Committee. The experts will be appointed within 4
working weeks and after having informed the
Applicant in order to ascertain whether any expert
may be challenged on grounds of partiality. One of
the experts will be appointed as chairman. The
Research Committee is responsible for ensuring that
the composition of the expert panel is balanced and
independent.
4) The evaluation will primarily include and be
founded on human intervention studies on which
the physiological effect to be claimed in the market-
ing is based. The number of studies necessary will be
decided from case to case, depending on how well-
established the physiological effect is considered to
be. Background information such as animal studies
may be used, when relevant, as supportive docu-
mentation and must be provided to the experts on
request.
5) The evaluation will consider the scientific documen-
tation in relation to the type of claim the Applicant
wishes to make  not the exact wording or other
formulation of the claim.
6) The evaluation shall be completed within 90 days of
receiving the documentation. If additional time is
needed, for example due to the scope of the
documentation, an agreement will be reached from
case to case. The expert panel must aim for a
unanimous evaluation. If this is not possible, a
majority decision is reached with right to express a
dissenting opinion in writing.
7) The Applicant must be given an opportunity to
comment on the evaluation before it is finalized.
8) If the Applicant does not accept the evaluation of
the expert panel, and reports this to SNF within
2 weeks, a new expert panel must be appointed, after
renewed consideration by the Research Committee,
with the assignment of making a new evaluation.
This shall be based on the report of the original
panel together with comments and any additional
documentation from the Applicant.
9) The assignment of the expert panel consists of
judging whether the submitted documentation is
qualitatively and quantitatively sufficient in relation
to the health benefit the company intends to claim in
the marketing. The responsibilities of SNF and its
Research Committee shall be limited to coordina-
tion of the evaluation process and a decision as to
whether to handle an application and appoint an
expert panel. The Research Committee will also
decide whether there are objective reasons to ap-
point a new expert panel, at the request of the
Applicant Company, in accordance with point 8.
10) The evaluation must be carried out confidentially.
The evaluation report will become public if and
when the product is put on the market with a
product-specific physiological claim according to the
assessed application.
11) SNF will decide a fee for the evaluation, which must
be paid to SNF together with an administrative fee.
12) In labelling and marketing it is permitted to state
that the product has undergone evaluation of the
scientific documentation according to the Code.
This must be stated in a standardized text: ‘‘Doc-
umentation supporting the health benefits of this
product has been evaluated in accordance with the
Food Sector’s Code of Practice hp-info.nu’’. Neither
SNF nor the experts’ names may be mentioned in
the marketing.
13) Appeals against the treatment of the application by
the Research Committee, according to 9 above, are
to be lodged with the Assessment Board for Diet
Health Information (BKH).
14) The Research Committee can, if the scientific
situation warrants, decide upon a renewed investiga-
tion.
Company
SNF Swedish Nutrition Foundation
SNF Research Committee
Panel of experts
(minimum of 3)
Statement concerning
scientific documentation
(Published on hp-info.nu once the product is
put on the market with the product-specific
physiological claim to which the application
refers.)
Fig. 1. General model for processing of applications for product-
speciﬁc physiological claims.
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12515) The evaluation will in addition follow applicable
parts of Council of Europe’s Policy Statements
concerning Nutrition, Food Safety and Consumer
Health: Guidelines Concerning Scientific Substan-
tiation of Health-Related Claims for Functional
Foods (can be downloaded in pdf format from
www.snf.ideon.se).
Nils-Georg Asp
SNF Swedish Nutrition Foundation
Ideon Science Park
SE-223 70 Lund
Sweden
Tel: 46 46 286 22 80
Fax: 46 46 286 22 81
E-mail: asp@snf.ideon.se
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